Antiangiogenic therapy for breast cancer

被引：0
作者：
Dorte Lisbet Nielsen
Michael Andersson
Jon Lykkegaard Andersen
Claus Kamby
机构：
[1] University of Copenhagen,Department of Oncology, Herlev Hospital
[2] University of Copenhagen,Department of Oncology, Finsen Centre, Rigshospitalet
来源：
Breast Cancer Research | / 12卷
关键词：
Vascular Endothelial Growth Factor; Bevacizumab; Docetaxel; Trastuzumab; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria.
引用
收藏
相关论文
共 1074 条
[21]  
Ramaswamy B(2010)Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer J Clin Oncol 28 3239-131
[22]  
Elias AD(2009)RIBBON-1: a randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer J Clin Oncol 27 abstract 1005-2019
[23]  
Kelbick NT(2010)A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) J Clin Oncol 28 abstract 1005-784
[24]  
Dodley A(2009)RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer Cancer Res 69 abstract 42-624
[25]  
Morrow M(2010)Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC) J Clin Oncol 28 abstract 1021-119
[26]  
Hauger M(2009)A phase II trial investigating if bevacizumab in combination with hormone therapy reverse acquired estrogen indepence in metastatic breast cancer patients J Clin Oncol 27 abstract e12027-2189
[27]  
Allen J(2006)Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) J Clin Oncol 24 abstract 3050-4655
[28]  
Roades C(2009)Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer J Clin Oncol 27 abstract 1091-3376
[29]  
Kendra K(2009)N0539 Phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group trial Cancer Res 69 abstract 4096-2376
[30]  
Chen HX(2008)A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or III breast cancer J Clin Oncol 26 abstract 562-671
12345678910